News Image

Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial

Provided By GlobeNewswire

Last update: Oct 14, 2024

MENLO PARK, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that a new study titled, Impact of TearCare on Reading Speed in Patients with Dry Eye Disease, has been published in the peer-reviewed journal Clinical Ophthalmology.

Read more at globenewswire.com

SIGHT SCIENCES INC

NASDAQ:SGHT (7/24/2025, 10:38:22 AM)

3.76

-0.02 (-0.53%)



Find more stocks in the Stock Screener

Follow ChartMill for more